MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318251 | Name: Methylprednisolone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Methylprednisolone is a synthetic glucocorticoid or corticosteroid drug. Common uses include arthritis therapy and short-term treatment of bronchial inflammation or acute bronchitis due to various respiratory diseases. It is used both in the treatment of acute periods and long-term management of autoimmune diseases, most notably systemic lupus erythematosus. It is also used as a treatment for multiple sclerosis. It is on the WHO Model List of Essential Medicines.

Chemical Structure

Methylprednisolone
Methylprednisolone
CAS#83-43-2

Theoretical Analysis

MedKoo Cat#: 318251

Name: Methylprednisolone

CAS#: 83-43-2

Chemical Formula: C22H30O5

Exact Mass: 374.2093

Molecular Weight: 374.47

Elemental Analysis: C, 70.56; H, 8.07; O, 21.36

Price and Availability

Size Price Availability Quantity
500mg USD 285.00 2 Weeks
1g USD 485.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Methylprednisolone, Medrol, Solu-Medrol, Metipred, Urbason
IUPAC/Chemical Name
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
InChi Key
VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChi Code
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
SMILES Code
C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Appearance
White to off-white crystalline powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Methylprednisolone is a synthetic glucocorticoid or corticosteroid drug.
In vitro activity:
In addition to its potent anti-inflammatory and antioxidant properties, this study recently discovered a selective antiapoptotic effect of MP (methylprednisone) on oligodendrocytes via the activation of the glucocorticoid receptor (GR) and the upregulation of bcl-X(L), a splicing isoform of the bcl-x gene. The GR and STAT5 complex is present on the STAT5-binding site of the bcl-x promoter region in oligodendrocytes; the overexpression of an activated form of STAT5 prevents alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced oligodendrocyte cell death; and this prevention is lost when the STAT5 gene is knocked down. Reference: J Neurosci. 2009 Feb 18;29(7):2022-6. https://pubmed.ncbi.nlm.nih.gov/19228956/
In vivo activity:
To examine whether MP (methylprednisone) demonstrated this selective protection in vivo, neuronal and oligodendrocyte survival was assessed in rats subjected to spinal cord injury (SCI); groups of rats were treated with or without MP in the presence or absence of RU486. Eight days after SCI, MP significantly increased oligodendrocytes (CC-1-immunoreactive cells) after SCI, but neuronal (neuronal-specific nuclear protein-immunoreactive cells) number remained unchanged; RU486 reversed this protective effect. MP also inhibited SCI-induced decreases in Bcl-x(L) and caspase-3 activation. Reference: J Neurosci. 2008 Mar 19;28(12):3141-9. https://pubmed.ncbi.nlm.nih.gov/18354017/
Solvent mg/mL mM comments
Solubility
DMSO 64.4 171.88
DMSO:PBS (pH 7.2) (1:1) 0.5 1.34
Ethanol 5.5 14.69
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 374.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Xu J, Chen S, Chen H, Xiao Q, Hsu CY, Michael D, Bao J. STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J Neurosci. 2009 Feb 18;29(7):2022-6. doi: 10.1523/JNEUROSCI.2621-08.2009. PMID: 19228956; PMCID: PMC2662324. 2. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, Bähr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003 Aug 6;23(18):6993-7000. doi: 10.1523/JNEUROSCI.23-18-06993.2003. PMID: 12904460; PMCID: PMC6740669. 3. Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY, Xu J. Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci. 2008 Mar 19;28(12):3141-9. doi: 10.1523/JNEUROSCI.5547-07.2008. PMID: 18354017; PMCID: PMC2748666. 4. Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB. Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci. 1999 Jul;11(7):2453-64. doi: 10.1046/j.1460-9568.1999.00666.x. PMID: 10383635.
In vitro protocol:
1. Xu J, Chen S, Chen H, Xiao Q, Hsu CY, Michael D, Bao J. STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J Neurosci. 2009 Feb 18;29(7):2022-6. doi: 10.1523/JNEUROSCI.2621-08.2009. PMID: 19228956; PMCID: PMC2662324. 2. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, Bähr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003 Aug 6;23(18):6993-7000. doi: 10.1523/JNEUROSCI.23-18-06993.2003. PMID: 12904460; PMCID: PMC6740669.
In vivo protocol:
1. Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY, Xu J. Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci. 2008 Mar 19;28(12):3141-9. doi: 10.1523/JNEUROSCI.5547-07.2008. PMID: 18354017; PMCID: PMC2748666. 2. Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB. Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci. 1999 Jul;11(7):2453-64. doi: 10.1046/j.1460-9568.1999.00666.x. PMID: 10383635.
1: Cheung V, Hoshide R, Bansal V, Kasper E, Chen CC. Methylprednisolone in the management of spinal cord injuries: Lessons from randomized, controlled trials. Surg Neurol Int. 2015 Aug 24;6:142. doi: 10.4103/2152-7806.163452. eCollection 2015. Review. PubMed PMID: 26392918; PubMed Central PMCID: PMC4553662. 2: Hurlbert RJ. Methylprednisolone for the treatment of acute spinal cord injury: point. Neurosurgery. 2014 Aug;61 Suppl 1:32-5. doi: 10.1227/NEU.0000000000000393. Review. PubMed PMID: 25032528. 3: Mi R, Yin Q, Wei X, Ai H, Song Y. [Fresh frozen plasma and Rituximab in combination with high dose methylprednisolone for the treatment of relapsed and refractory chronic lymphocytic leukemia: three cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2014 Aug;35(8):755-7. doi: 10.3760/cma.j.issn.0253-2727.2014.08.021. Review. Chinese. PubMed PMID: 25152130. 4: Fehlings MG, Wilson JR, Cho N. Methylprednisolone for the treatment of acute spinal cord injury: counterpoint. Neurosurgery. 2014 Aug;61 Suppl 1:36-42. doi: 10.1227/NEU.0000000000000412. Review. PubMed PMID: 25032529. 5: Harrop JS. Spinal cord injury: debating the efficacy of methylprednisolone. Neurosurgery. 2014 Aug;61 Suppl 1:30-1. doi: 10.1227/NEU.0000000000000391. Review. PubMed PMID: 25032527. 6: Rijsdijk M, van Wijck AJ, Kalkman CJ, Yaksh TL. The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery. Anesth Analg. 2014 May;118(5):1097-112. doi: 10.1213/ANE.0000000000000161. Review. PubMed PMID: 24781577. 7: İncecik F, Hergüner MÖ, Yıldızdaş D, Yılmaz M, Mert G, Horoz ÖO, Altunbaşak Ş. Posterior reversible encephalopathy syndrome due to pulse methylprednisolone therapy in a child. Turk J Pediatr. 2013 Jul-Aug;55(4):455-7. Review. PubMed PMID: 24292045. 8: Kauffman CA, Pappas PG, Patterson TF. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med. 2013 Jun 27;368(26):2495-500. doi: 10.1056/NEJMra1212617. Epub 2012 Oct 19. Review. PubMed PMID: 23083312. 9: Tęsiorowski M, Potaczek T, Jasiewicz B, Sapa J, Zygmunt M. [Methylprednisolone- acute spinal cord injury, benefits or risks?]. Postepy Hig Med Dosw (Online). 2013 Jun 26;67:601-9. doi: 10.5604/17322693.1054873. Review. Polish. PubMed PMID: 23800640. 10: D'Agnolo HM, Drenth JP. High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature. Neth J Med. 2013 May;71(4):199-202. Review. PubMed PMID: 23723114. 11: Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2013 Feb 28;2:CD002265. doi: 10.1002/14651858.CD002265.pub3. Review. PubMed PMID: 23450535. 12: García Ponte L, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2012 Nov;26 Suppl 6:9-13. doi: 10.1111/j.1468-3083.2012.04711.x. Review. PubMed PMID: 23067432. 13: Breslin K, Agrawal D. The use of methylprednisolone in acute spinal cord injury: a review of the evidence, controversies, and recommendations. Pediatr Emerg Care. 2012 Nov;28(11):1238-45; quiz 1246-8. doi: 10.1097/PEC.0b013e3182724434. Review. PubMed PMID: 23128657. 14: Pettiford JN, Bikhchandani J, Ostlie DJ, St Peter SD, Sharp RJ, Juang D. A review: the role of high dose methylprednisolone in spinal cord trauma in children. Pediatr Surg Int. 2012 Mar;28(3):287-94. doi: 10.1007/s00383-011-3012-3. Epub 2011 Oct 13. Review. PubMed PMID: 21994079. 15: Arora B, Suresh S. Spinal cord injuries in older children: is there a role for high-dose methylprednisolone? Pediatr Emerg Care. 2011 Dec;27(12):1192-4. doi: 10.1097/PEC.0b013e31823b4d06. Review. PubMed PMID: 22158284. 16: Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011 May;25(5):508-15. doi: 10.1111/j.1468-3083.2010.03942.x. Review. PubMed PMID: 21492244. 17: Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):251-8. doi: 10.1111/j.1468-3083.2010.03789.x. Review. PubMed PMID: 21294777. 18: Bílková E, Imramovský A, Sedlák M. Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates. Curr Pharm Des. 2011;17(32):3577-95. Review. PubMed PMID: 22074428. 19: Lukáš R, Zýková I, Barsa P, Srám J. [Current role of methylprednisolone in the treatment of acute spinal cord injury]. Acta Chir Orthop Traumatol Cech. 2011;78(4):305-13. Review. Czech. PubMed PMID: 21888840. 20: Tardieu M, Deiva K. [Acute encephalitis in intensive care unit: how to use pulses of methylprednisolone]. Arch Pediatr. 2010 Jun;17(6):991-2. doi: 10.1016/S0929-693X(10)70214-1. Review. French. PubMed PMID: 20654996.